MET and cancer: Although highly expression of PD-L1, the role of immunotherapy in patients with EGFR-mutated NSCLC remains controversial.[7] And There are several small samples of clinical trial data describing the efficacy of EGFR-TKIs combined with MET inhibition in EGFR-mutant cancers with acquired resistance to Met amplification.[8,9] Therefore, a decision was made to proceed with the third-generation EGFR-TKI osimertinib (80 mg, QD) combined with the MET inhibitor crizotinib (250 mg, BID) from October 17, 2018.